Company news

Zhejiang Hisun Pharmaceutical Co., Ltd. news in 2025

Zhejiang Hisun Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2026

December 26, 2025

Announcement on Obtaining the Notice on Approval of Drug Supplement Application

December 23, 2025

Announcement on HS387 Tablets Obtaining the U.S. FDA Approval for Clinical Trials of a New Drug

December 22, 2025

Announcement on the Subsidiary Obtaining New Veterinary Drug Registration Certificate

December 18, 2025

Notice on Convening the 1st Extraordinary General Meeting in 2026

December 17, 2025

Announcement on the Wholly-Owned Subsidiary Receiving the CEP Certificate for Everolimus API

December 12, 2025

Announcement on Progress in Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.

December 10, 2025

Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs

December 3, 2025

Announcement on Resolutions of the 9th Meeting of the 10th Board of Directors

November 19, 2025

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

November 12, 2025

Announcement on Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.

November 11, 2025

Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025

November 5, 2025

Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement

October 29, 2025

Report for Q3 2025

October 27, 2025

Announcement on Convening the Q3 2025 Performance Briefing

October 24, 2025

Announcement on the Revocation of the "GMP Non-Compliance Statement" for the Taizhou Factory by the European Union

October 19, 2025

Announcement on the Company’s Products Obtaining the Self-GRAS Certification from the United States

October 9, 2025

Announcement on Resolutions of the 7th Meeting of the 10th Board of Directors

September 16, 2025

Announcement on the Obtainment of CEP Certificate for Tigecycline Active Pharmaceutical Ingredient

September 12, 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

September 10, 2025

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025

September 3, 2025

Announcement on Making Provisions for Assets Impairment

August 25, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 19, 2025

Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Bedaquiline Fumarate API

July 23, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trials

July 1, 2025

Announcement on Resolution of the 4th Meeting of the 10th Board of Directors

June 19, 2025

Announcement on Completing Changes in Registered Capital and Business Scope and Obtaining Renewed Business License

June 5, 2025